-+ 0.00%
-+ 0.00%
-+ 0.00%

CG Oncology appoints Jim DeTore as CFO

PUBT·04/13/2026 12:30:59
Listen to the news
CG Oncology appoints Jim DeTore as CFO
  • CG Oncology appointed Jim DeTore as chief financial officer on April 13, 2026.
  • DeTore has served as interim principal financial and accounting officer since November 2025 under a consulting agreement with Monomoy Advisors.
  • His prior roles include CFO at Neurogastrx from June 2021 to June 2025.
  • Earlier, he provided CFO services as an independent consultant from March 2017 to May 2021.
  • DeTore previously held CFO posts at Proteostasis Therapeutics and Bluebird Bio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-152044), on April 13, 2026, and is solely responsible for the information contained therein.